Ascendiant Capital Markets Increases PAVmed (NASDAQ:PAVM) Price Target to $20.00

PAVmed (NASDAQ:PAVM) had its price objective increased by equities researchers at Ascendiant Capital Markets from $19.00 to $20.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.00.

PAVmed Trading Down 1.1%

Shares of NASDAQ:PAVM opened at $0.44 on Monday. The firm has a 50 day moving average of $0.46 and a 200-day moving average of $0.59. PAVmed has a 12 month low of $0.30 and a 12 month high of $1.32. The stock has a market capitalization of $9.55 million, a PE ratio of 0.38 and a beta of 1.07.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the period. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.